ABB shrugs off uncertainties to post big jump in orders

ABB shrugs off uncertainties to post big jump in orders


Gianluca Colla | Bloomberg | Getty Images

ABB shrugged off rising global uncertainties like the war in Ukraine and increasing inflation to post a big jump in orders during the engineering and technology company’s first quarter.

The maker of factory robots and industrial drives increased its new order intake by 21% to $9.37 billion, the highest level since ABB sold its power grids business in June 2020.

The increase came despite war in Ukraine, components shortages, rising inflation and the reemergence of Covid-19 in China, factors which caused the International Monetary Fund to reduce its global growth forecast this week. 

“ABB has started the year with a promising performance in the face of multiple external uncertainties,” CEO Bjorn Rosengren said.

Its shares were indicated 3.1% higher in premarket activity on the Swiss exchange.

ABB, which competes with Germany’s Siemens and France’s Schneider Electric, is seen as a barometer for the global economy with its drives and control systems used in the transport sector and factories.

Rosengren described the war, which Moscow calls a “special operation”, as a “human tragedy”, with the company suspending new orders in Russia, a small market accounting for only 1-2% of its annual revenue.

Still, Rosengren said ABB, was seeing strong customer activity, with most regions developing favourably.

“Notably, the high order intake was driven by high general customer activity and not by large orders,” Rosengren said.

ABB reported a first-quarter operating profit before interest, tax and amortisation (EBITA) of $997 million, beating the $946 million in a company-gathered poll of analysts.

Net profit rose 20% to $604 million, beating forecasts of $562 million. Revenue of $6.96 billion missed forecasts.

For the second quarter, ABB said it anticipates the underlying market activity to remain broadly similar to the start of the year, with higher revenue also boosting profit margins.

The company cautioned this expectation was based on no escalation of lockdowns in China, which since March has been grappling with the worst COVID-19 outbreak since the virus emerged in late-2019.

ABB kept the outlook it gave in January when it said it expected a steady margin improvement towards a 2023 target of at least 15%.

During the first quarter the company posted an EBITA margin of 14.3%, higher than a year earlier, as higher volumes and prices helped it offset cost inflation for raw materials, components.



Source

Several killed after fire in Swiss ski resort bar
World

Several killed after fire in Swiss ski resort bar

Police officers walk at the site of an explosion that ripped through a bar in Crans-Montana on January 1, 2026. Several people were killed and others injured when an explosion ripped through a bar in the luxury Alpine ski resort town of Crans Montana, Swiss police said early on January 1. Maxime Schmid | Afp […]

Read More
U.S. grants TSMC annual licence to import U.S. chipmaking tools into China
World

U.S. grants TSMC annual licence to import U.S. chipmaking tools into China

TSMC offices in San Jose, California, on April 18, 2024. Bloomberg | Bloomberg | Getty Images The U.S. government has granted an annual licence to Taiwan Semiconductor Manufacturing to import U.S. chip manufacturing equipment to its facilities in Nanjing, China, the chipmaker said on Thursday. The approval “ensures uninterrupted fab operations and product deliveries,” the […]

Read More
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market
World

Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market

Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk’s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker […]

Read More